Skip to content
Screener

Rapport Therapeutics, Inc. RAPP Q3 2025 earnings

Reported November 6, 2025 · Before market open

EPS-$0.71Beat by $0.06
EPS estimate-$0.77

Next report

Nov 5, 2026 (in 3 months)
EPS estimate-$1.21

Financials

Q3 2025

Income statement

See full
Operating income-$30.0M-38.6%
Net income-$26.9M-53.5%
EPS (diluted)-$0.71-42.0%

Balance sheet

See full
Cash & equivalents$251.4M+539%
Total debt$11.9M+619%
Total equity$511.6M+58.3%
Total assets$535.3M+61.7%

Cash flow

See full
Operating cash flow-$17.5M-6.4%
CapEx$134.0K-4.3%
Free cash flow-$17.6M-6.3%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.37B+82.8%
Enterprise value$1.13B+58.8%

Returns & leverage

See full
Return on equity-23.4%—
Debt / equity0×0.0×
Current ratio36.4×-9.5×

FAQ

When did Rapport Therapeutics, Inc. report Q3 2025 earnings?
Rapport Therapeutics, Inc. (RAPP) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Rapport Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Rapport Therapeutics, Inc. reported eps of $-0.71 for Q3 2025.
Did Rapport Therapeutics, Inc. beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.77 by $0.06.
How did Rapport Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 42.0% from $-0.50.
Where can I find Rapport Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-268072) and the 10-Q periodic report (0001193125-25-268096) directly on SEC EDGAR. The filing index links above go to sec.gov.